Yale University’s Cartesian Therapeutics RNAC Stock Holding History

Yale University’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100,000	Closed	-$1.61M	–	4
2024 Q3	$1.61M	Buy	+100,000	New	+$1.56M	66.3%	1

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Yale University's RNAC Position: Q4 2024 in Review

Yale University sold out of Cartesian Therapeutics (RNAC) in Q4 2024, closing a stake of 100,000 shares — an estimated $1.61M sold.

Yale University first reported a position in RNAC in Q3 2024 and held it in 1 quarter. The position peaked at $1.61M in Q3 2024. 68 funds tracked by Wall St. Rank hold RNAC as of Q4 2024.

Yale University reported no remaining Cartesian Therapeutics position as of Q4 2024 after selling out during the quarter.
Yale University sold 100,000 Cartesian Therapeutics shares in Q4 2024, an estimated $1.61M.
Yale University first reported a position in Cartesian Therapeutics in Q3 2024 and held it in 1 quarter.
Yale University's Cartesian Therapeutics position peaked at $1.61M in Q3 2024.
68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2024.

Based on Yale University's 13F filing for Q4 2024, filed 14 Feb 2025.